免费日韩片_欧美成人精品一区二区男人小说_国产乱码一区二区三区四区_国产精品国产三级国产aⅴ入口_成人看的污污超级黄网站免费_欧美一级在线免费观看_成人午夜免费无码福利片_国产乱人伦偷精品视频色欲_aaa少妇高潮大片免费看_国产精品1234_亚洲精品国产suv一区88_中文字字幕在线中文无码_精品亚洲区_午夜九九九_国产av国片精品jk制服丝袜_色综合亚洲_亚洲成av人片无码bt种子下载_欧美色就色_精品少妇的一区二区三区四区_男人用嘴添女人下身免费视频

(Xinhua)
Updated: 2007-09-20 17:19

Pharmaceutical manufacturers would be given a 24-hour deadline to recall problematic drugs that could cause serious harm to takers in a draft plan on China's drug safety.

The State Food and Drug Administration (SFDA) published a draft on drug recall on Thursday to solicit public feedback.

It classified the problem drugs that must be recalled into three categories, with the first being potentially fatal and harmful drugs, which must be recalled in 24 hours.

The second category was drugs that may cause temporary health problems and producers had three days to recall these.

The third category was drugs that must be recalled within seven days for other reasons such as improper packaging.

The plan requires manufacturers to promptly analyse information and feedback from hospitals, retailers and users, and to investigate and evaluate potentially unsafe drugs.

If a potential danger is confirmed, the makers must recall the product, inform retailers, users and the public of the possible effects.

The draft allows the government to revoke the manufacturing license if the drugs cause serious harm or the makers fail to recall the drugs or inform the public promptly.

If retailers and hospitals find problems, they must immediately stop selling and using the product, inform the makers and providers, and submit a timely report to the quality supervision authorities.

If they fail to do so, they face fines ranging from 1,000 (US$132) to 50,000 yuan or revocation of licenses in serious cases.

On September 16, the Shanghai municipal government ordered Shanghai Hualian Pharmaceutical Co. to recall leukemia drugs methotrexate and cytarabine hydrochloride after they had caused adverse reactions, including difficulty in walking and retention of urine, in some patients.

The government has tried to strengthen supervision of pharmaceutical and biological products this year. In July, the SFDA revoked the production license of Guangdong Baiyi Pharmaceutical Company for making blood products from a donor infected with hepatitis C.